Nearly 20,000 babies in Uganda are born with sickle cell disease every year. Across Africa, many children with the inherited blood disorder die before their fifth birthday because doctors diagnose them too late.
Uganda’s response so far is practical, not futuristic: test early, treat early and keep the medicine flowing. Gene therapy could one day offer a permanent cure, but for most patients, it’s still out of reach.
One Family’s Ordeal
Irene Nalukwago’s daughter was born healthy at a hospital in Kayunga, east of the capital, Kampala. At six months, she began falling sick and becoming anaemic. Transfusions came almost every week, and the child suffered considerable pain. Doctors suspected a deeper problem. Tests confirmed sickle cell disease.
She’s 12 now. Repeated attacks have taken a heavy toll. “She became paralysed on the left side of her body; I just had to carry her,” Nalukwago said.
Her story reflects the cost of late diagnosis. Thousands of children have gone years without early diagnosis or proper treatment.
Screening and a Daily Pill
Uganda has scaled up mandatory newborn screening across the country. That changes the timeline. Dr Isaac Tumusiime, medical officer at Kayunga Referral Hospital, said the clinic starts children on treatment very young. “All our children are started on hydroxyurea as early as nine months,” he said.
Hydroxyurea is an oral prescription medication. It reduces painful attacks and the need for blood transfusions, which means fewer emergency visits and less strain on hospital resources.
A steady supply matters as much as the prescription. “And there is continuous supply so there is good adherence to the treatment as well, so most of the children have managed to survive through this setup,” Tumusiime said.
The model depends on families. Patients at the Kayunga clinic are advised that routine check-ups can help them stay healthy and avoid life-threatening complications such as strokes. Doctors say regular monitoring can catch problems early, ease pressure on stretched health workers and give patients a better chance of longer, healthier lives.
The Cure That Isn’t Affordable Yet
Some countries have rolled out gene therapy that could potentially end years of suffering. Uganda isn’t among those with broad access. Tumusiime said parents are encouraged to manage their children with hydroxyurea “with a hope that maybe one day gene therapy could be affordable.”
He chose the word affordable. For now, the therapy remains out of reach for most people who need it.
Why This Matters:
Uganda’s approach shows how far a low-tech treatment, supplied consistently, can go before expensive breakthroughs arrive. Screening at birth and a reliable supply of an oral medication have helped most children at the Kayunga clinic survive, according to its medical officer. That’s a measurable return on basic public health functions done well. The approach also has limits. Health workers are stretched, and a cure that most families can’t afford doesn’t help them. Whether gene therapy becomes affordable will depend on cost, and until then, steady adherence by families and dependable supply remain the practical foundation of care.